Tags : BioIntelliSense

Weekly Snapshot (Jul 06 – 10, 2020)

1. LEO Reports the US FDA’s Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis Published Date: Jul 10, 2020 | Tags: LEO, Reports, US, FDA, Acceptance, BLA, Tralokinumab, Treat, Adults, Moderate to Severe, Atopic Dermatitis 2. Philips Collaborates with BioIntelliSense to Enhance Remote Patient Monitoring Published Date:  Jul 10, […]Read More

Philips Collaborates with BioIntelliSense to Enhance Remote Patient Monitoring

Shots: Royal Philips collaborated with BioIntelliSense, to integrate its BioSticker medical device into Philips’ RPM offering to help monitor at-risk patients from the hospital into the home Addition of multi-parameter sensors aid monitoring across multiple chronic conditions with medical-grade vital signs for physicians to remotely track core symptoms, including COVID-19 The BioSticker is a single-use, […]Read More

BioIntelliSense’s BioSticker Receives FDA’s 510 (k) Clearance for Month-Long Vitals

Shots: BioIntelliSense launches its medical-grade Data-as-a-Service (DaaS) platform and has received 510(k) clearance for BioSticker on-body sensor for scalable remote care in the US The company has developed BioSticker device in collaboration with UC Health and its CARE Innovation Center to monitor the patient’s health in their home, thus reducing hospitalizations, emergency department visits and […]Read More